CliffBio
small molecule

ADZENYS ER

AMPHETAMINE

Loss of exclusivityJune 2032latest FDA-listed patent expiry
CompanyNEOS →View the full company profile on CliffBio

Drug detail

Brand nameADZENYS ER
Active ingredientAMPHETAMINE
StrengthEQ 1.25MG BASE/ML
Dosage formSUSPENSION, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
8709491June 2032product
9017731June 2032product
9265737June 2032product

More from NEOS

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ADZENYS ER patent cliff — loss of exclusivity June 2032 | CliffBio